Valuation : BriaCell Therapeutics Corp.

Market Cap 29.89M 25.66M 24.02M 22M 41.44M 2.85B 41.55M 284M 111M 1.44B 112M 110M 4.76B P/E 2024
-2.56x
P/E 2025 -0.12x
Enterprise Value 12.02M 10.32M 9.66M 8.85M 16.67M 1.15B 16.72M 114M 44.73M 579M 45.15M 44.17M 1.92B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
99.49%
Yield 2024 *
-
Yield 2025 -
1 day-8.19%
1 week-5.84%
Current month+7.05%
1 month+2.38%
3 months+2.18%
6 months-0.96%
Current year-47.35%
1 week 4.78
Extreme 4.78
5.62
1 month 4.61
Extreme 4.61
5.75
Current year 3.68
Extreme 3.68
16.5
1 year 3.68
Extreme 3.68
20.4
3 years 3.68
Extreme 3.68
1,510.5
5 years 3.68
Extreme 3.68
2,362.5
10 years 3.68
Extreme 3.68
11,250.11
Manager TitleAgeSince
Chief Executive Officer 70 2016-10-31
Director of Finance/CFO 54 2016-01-31
Chief Tech/Sci/R&D Officer 65 2022-02-15
Director TitleAgeSince
Director/Board Member 70 2016-10-31
Chairman 41 2019-04-23
Director/Board Member 74 2019-03-06
Date Insider Type Main position Quantity % Market Cap.
7/7/26 Tax

Director

45,000 0.5173%
7/7/26 Tax

Director

15,000 0.1724%
7/7/26 Option

Chief Financial Officer

28,257 0.3248%
Change 5-day change 1-year change 3-year change Capi.($)
-8.19%-5.84%-50.86%-99.66% 35.21M
+3.31%-3.70%+61.03%+103.64% 70.42B
+1.09%+2.51%+49.34%+93.39% 65.4B
-1.03%+0.46%+8.14%-5.28% 28.28B
-2.41%-2.95%-9.77%+455.82% 27.16B
-0.10%-1.57%+61.73%+10.94% 26.57B
+1.02%+6.43%+269.42%+420.34% 20.61B
+0.37%+1.21%+36.55%-15.78% 20.09B
-1.43%-4.28%+13.44%+531.90% 15.87B
-1.50%+2.92%+43.50%+151.30% 13.9B
Average -0.97%+1.54%+48.25%+164.66% 28.83B
Weighted average by Cap. +0.60%+0.94%+56.30%+155.44%

Financials

2024 2025
Net sales - -
Net income -4.79M -4.11M -3.85M -3.53M -6.64M -458M -6.66M -45.6M -17.82M -231M -17.99M -17.6M -763M -26.31M -22.59M -21.15M -19.36M -36.48M -2.51B -36.58M -250M -97.88M -1.27B -98.79M -96.65M -4.19B
Net Debt -862K -740K -693K -634K -1.2M -82.34M -1.2M -8.2M -3.21M -41.5M -3.24M -3.17M -137M -17.87M -15.34M -14.36M -13.15M -24.77M -1.71B -24.84M -170M -66.46M -860M -67.08M -65.63M -2.85B
Logo BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells. The Company is advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer. It is also developing personalized off-the-shelf immunotherapies, Bria-OTS and Bria-OTS+, which provides a platform technology to develop personalized off-the-shelf immunotherapies for numerous types of cancer, and a soluble CD80 protein therapeutic which act both as a stimulator of the immune system, as well as an immune checkpoint inhibitor. Its pipeline also includes Bria-IMT + CPI, Bria-BRES/BRES+, Bria-PROS+, Bria-LUNG+ and Bria-MEL+.
Employees
16
Date Price Change Volume
26-08-27 CA$5.160 -8.19% 18,436
26-08-26 CA$5.620 +9.34% 9,906
26-08-25 CA$5.140 +6.64% 18,603
26-08-24 CA$4.820 -13.31% 25,391
26-08-21 CA$5.560 +1.46% 9,309

Quarterly revenue - Rate of surprise